BOLD - CIK 0001782303
The table below shows Boundless Bio, Inc.'s cash flow statement line items across its last 3 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Operating cash flow | -$46.66M | -$60.84M | -$46.85M |
| Capital expenditure | $546.00K | $2.54M | $633.00K |
| Investing cash flow | $37.80M | -$26.10M | -$38.26M |
| Dividends paid | - | - | - |
| Stock buybacks | - | - | - |
| Financing cash flow | $141.00K | $89.82M | $97.90M |
Boundless Bio, Inc. reported operating cash flow of -$46.66M for fiscal year 2025. That is up 23.3% from -$60.84M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.